BrightSpring Health price target raised to $55 from $53 at UBS

UBS analyst AJ Rice raised the firm’s price target on BrightSpring Health (BTSG) to $55 from $53 and keeps a Buy rating on the shares. At the investor day event in Louisville, management highlighted strong historical adjusted EBITDA compound annual growth rates of 18%-19% and projected continued 15%-20% CAGR growth from 2026-2028, positioning the company among the top performers in its peer group, the analyst tells investors in a research note. This trajectory is expected to generate at least $2B in additional capital availability through 2028 to support M&A and other priorities, with management targeting consistent double-digit growth across all business segments and citing no major long-term constraints beyond scale, UBS adds.